Related Experiment Video
Updated: Jun 8, 2026

Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
Published on: August 4, 2023
Conflicts of interest within the French regulatory agency: more progress needed
Abstract:
In November 2009, the French drug regulatory agency (Afssaps) published the second report on its mechanism for handling the conflicts of interest of outside experts performing tasks within Afssaps. Despite the statutory requirements for experts to disclose their conflicts of interest every year, some of these experts do not. There is no procedure in place to verify their disclosure statements. In contravention of Afssaps's rules, more than half of the experts whose conflicts of interest were rated as "major" did not leave the room while a case with which they had ties was examined. Above all, expert evaluation that is free from the influence of drug companies needs to be encouraged and its value recognised.
Related Concept Videos
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Regulation
Global Regulatory Systems
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Bioequivalence studies: Biowaivers
